NEW YORK (GenomeWeb News) - Illumina and ReaMetrix plan to develop molecular diagnostic panels for several diseases, the companies said today.
The panels will "help predict the risk of disease, enable earlier intervention, and guide therapy," Jay Flatley, Illumina president and CEO, said in a statement.
Terms of the agreement call for Illumina to supply its VeraCode technology and other reagents while ReaMetrix will develop, validate, and market the panels.
Already have a GenomeWeb or 360Dx account?Login Now.
A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.
Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.
In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.
A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.
This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.
This webinar will discuss a proximity ligation-based method for studying structural variation in formalin-fixed paraffin-embedded (FFPE) tissue.